- Home
- ARDX vs SYRE Comparison
ARDX vs SYRE Comparison
Compare ARDX & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARDX
- SYRE
- Stock Information
- Founded
- ARDX 2007
- SYRE 2013
- Country
- ARDX United States
- SYRE United States
- Employees
- ARDX N/A
- SYRE N/A
- Industry
- ARDX Biotechnology: Pharmaceutical Preparations
- SYRE Biotechnology: Pharmaceutical Preparations
- Sector
- ARDX Health Care
- SYRE Health Care
- Exchange
- ARDX Nasdaq
- SYRE Nasdaq
- Market Cap
- ARDX 1.3B
- SYRE 1.2B
- IPO Year
- ARDX 2014
- SYRE 2016
- Fundamental
- Price
- ARDX $4.79
- SYRE $15.30
- Analyst Decision
- ARDX Strong Buy
- SYRE Strong Buy
- Analyst Count
- ARDX 9
- SYRE 8
- Target Price
- ARDX $10.61
- SYRE $51.50
- AVG Volume (30 Days)
- ARDX 3.9M
- SYRE 651.5K
- Earning Date
- ARDX 05-01-2025
- SYRE 05-08-2025
- Dividend Yield
- ARDX N/A
- SYRE N/A
- EPS Growth
- ARDX N/A
- SYRE N/A
- EPS
- ARDX N/A
- SYRE N/A
- Revenue
- ARDX $333,615,000.00
- SYRE N/A
- Revenue This Year
- ARDX $14.26
- SYRE N/A
- Revenue Next Year
- ARDX $32.49
- SYRE N/A
- P/E Ratio
- ARDX N/A
- SYRE N/A
- Revenue Growth
- ARDX 168.06
- SYRE N/A
- 52 Week Low
- ARDX $4.32
- SYRE $15.26
- 52 Week High
- ARDX $9.33
- SYRE $40.84
- Technical
- Relative Strength Index (RSI)
- ARDX 37.46
- SYRE 32.29
- Support Level
- ARDX $4.68
- SYRE $16.71
- Resistance Level
- ARDX $5.56
- SYRE $18.28
- Average True Range (ATR)
- ARDX 0.25
- SYRE 1.21
- MACD
- ARDX -0.05
- SYRE -0.13
- Stochastic Oscillator
- ARDX 12.71
- SYRE 1.29
About ARDX Ardelyx Inc.
Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative, first-in-class medicines that meet significant unmet medical needs. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.